特步他林雾化吸入联合阿奇霉素治疗小儿支原体肺炎的临床疗效观察  

Clinical Observation of Terbutaline Atomization Inhalation Combined with Azithromycin in the Treatment of Mycoplasma Pneumonia in Children

作　　者：郭婷 GUO Ting(Department of Pediatrics,China Rongtong Medical Health Group Putian 95 Hospital,Putian 351100,China)

机构地区：[1]中国融通医疗健康集团莆田九十五医院儿科,莆田351100

出　　处：《中国医药指南》2024年第13期106-109,共4页Guide of China Medicine

摘　　要：目的 为小儿支原体肺炎患儿应用特步他林雾化吸入+阿奇霉素治疗,观察临床效果。方法 80例样本均来自中国融通医疗健康集团莆田九十五医院2023年2月至2024年2月收治的支原体肺炎患儿,采用随机数字表法分为对照组(40例,阿奇霉素)和观察组(40例,阿奇霉素+特步他林)。观察两组患儿症状缓解时间、炎症因子指标治疗有效率以及不良反应发生情况。结果 观察组患儿的发热、咳嗽、气喘、头痛症状缓解时间短于对照组(P <0.05)。治疗后,观察组的炎症因子指标低于对照组(P <0.05)。观察组患儿总有效率100%(40/40)高于对照组87.50%(35/40)(P <0.05)。两组不良反应发生率差异无统计学意义(P> 0.05)。结论 为小儿支原体肺炎患儿应用特步他林雾化吸入配合阿奇霉素治疗效果较好,患儿的症状缓解更快,有利于改善炎症因子指标,不良反应发生风险可控,安全性有保障。Objective To apply nebulized inhalation of terbutaline and azithromycin for the treatment of pediatric Mycoplasma pneumonia,and observe the clinical effect.Methods The 80 samples are all from the Mycoplasma pneumoniae children treated by Putian 95 Hospital of China Rongtong Medical Health Group from February 2023 to February 2024.They were divided into a control group(n=40,Azithromycin) and an observation group(n=40,Azithromycin + Terbutaline) using a random number table method.The symptom relief time,inflammatory factor index treatment effectiveness,and adverse reaction occurrence of the two groups of children were observed.Results The symptom remission time in observation group was shorter than that in control group(P<0.05).After treatment,the inflammatory factors in the observation group were lower than those in the control group(P<0.05).The effective rate of observation group was 100%(40/40),which was higher than that of control group 87.50%(35/40)(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Treatment of children with mycoplasma pneumonia using terbutaline nebulization inhalation combined with azithromycin shows better effects,with faster symptom relief,conducive to improving inflammatory factor indicators,controllable risk of adverse reactions,and guaranteed safety.

关 键 词：小儿支原体肺炎 特步他林 阿奇霉素 肾上腺素β2受体激动剂 炎症因子 

分 类 号：R725.6[医药卫生—儿科] R563.1[医药卫生—临床医学]